Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Cirrhosis

Cirrhosis

Subtypes of Cirrhosis

Liver Fibrosis 14 Primary biliary cholangitis 10 Decompensated liver cirrhosis 6 Fibrosis 5 End-stage liver disease 4 Keloid 4 Compensated cirrhosis 3 Acute decompensation of cirrhosis 1 Compensated MASH cirrhosis 1 Decompensated liver failure 1

78 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Cirrhosis

82 trials tracked for Cirrhosis: 27 in phase 3 or 4 and 2 with published results. The most-cited published study has 45 citations.

82Trials tracked
27Phase 3 & 4
0Recruiting
2With published results
Phase distribution
Phase 4 12 Phase 3 15 Phase 2 22 Phase 1 3 Other / NA 30
  1. Phase 4 The Safety/Efficacy of Rifaximin With/Without Lactulose in Participants With A History of Recurrent Hepatic Encephalopathy Completed · 45 cited
  2. Phase 3 Implications of Fecal Microbiota Transplantation in Modulating the Effects of Liver Cirrhosis Completed · 24 cited
  3. Phase 4 Study of Long-term Peg Intron vs. Colchicine in Non-responders. Completed
  4. Phase 4 Study to Evaluate the Safety and Efficacy of Daclatasvir/Sofosbuvir/Ribavirin for 16 Versus 24 Weeks for HCV Genotype 3 Cirrhotics Completed
  5. Phase 4 Sofosbuvir Based DAA Therapy in HIV/HCV Coinfected Pre or Post Liver Transplant Completed
  6. Phase 4 Efficacy and Safety of Anticoagulant Therapy in Portal Vein Thrombosis Completed
Show 44 more trials
  1. Phase 4 Ramelteon for Treatment of Insomnia in Cirrhosis Completed
  2. Phase 4 PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors) Completed
  3. Phase 4 Ropinirole for the Treatment of Muscle Cramps in Patients With Cirrhosis Completed
  4. Phase 4 Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis Completed
  5. Phase 4 Tolvaptan for Ascites in Cirrhotic Patients Completed
  6. Phase 4 Steroid Free Immunosuppression in Liver Transplantation Completed
  7. Phase 4 Adefovir Dipivoxil For The Treatment Of Patients With Chronic Hepatitis B Related Advanced Fibrosis Or Cirrhosis Completed
  8. Phase 3 A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin in US Veterans With Genotype 1 Chronic Hepatitis C Virus Infection Completed
  9. Phase 3 Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study Completed
  10. Phase 3 Is Adrenal Insufficiency Under-diagnosed in Hospitalized Cirrhosis Patients? Completed
  11. Phase 3 A Trial to Improve Quality of Life in People With Cirrhosis Completed
  12. Phase 3 Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment Completed
  13. Phase 3 Effects of Pegylated Interferon Alfa-2b and Ribavirin After Orthotopic Liver Transplantation in Subjects With Chronic Hepatitis C Recurrence (P04590AM3)(COMPLETED) Completed
  14. Phase 3 Use of Methacetin Breath Test to Predict Liver Failure in Patients With Cirrhosis Completed
  15. Phase 3 Efficacy and Safety of Peginterferon Alfa-2b and Ribavirin Therapy in Subjects With Type C Compensated Liver Cirrhosis (Study P05116) Completed
  16. Phase 3 A Trial to Investigate the Efficacy of OPC-41061 Administered at a Dose of 7.5 mg in Patients With Hepatic Edema Completed
  17. Phase 3 PEG-Intron Plus Rebetol Treatment of Chronic Hepatitis C Subjects Who Failed Response to Alpha-Interferon Plus Ribavirin (Study P02370) Completed
  18. Phase 3 A Study to Investigate Pharmacodynamics and Pharmacokinetics of OPC-41061 in Patients With Hepatic Edema Completed
  19. Phase 3 A Trial of OPC-41061 in Patients With Hepatic Edema - Investigation of the Safety of Treatment at 7.5 mg Beyond 7 Days and of the Effect of Dose Escalation to 15 mg Completed
  20. Phase 3 Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis Completed
  21. Phase 3 Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569) Completed
  22. Phase 2 A Study of Experimental Medication BMS-986263 in Adults With Advanced Hepatic Fibrosis After Cure of Hepatitis C Completed
  23. Phase 2 Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients Completed
  24. Phase 2 FMT in Cirrhosis and Hepatic Encephalopathy Completed
  25. Phase 2 Sofosbuvir and Ribavirin in Patients With Chronic HCV With Cirrhosis and Portal Hypertension With or Without Liver Decompensation Completed
  26. Phase 2 A Study of Safety and Efficacy of HPN-100 in Subjects With Cirrhosis and Episodic Hepatic Encephalopathy Completed
  27. Phase 2 A Study of IDN-6556 in Subjects With Liver Cirrhosis Completed
  28. Phase 2 A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV Completed
  29. Phase 2 VE303 for Treatment of Hepatic Encephalopathy (HE) Completed
  30. Phase 2 A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Completed
  31. Phase 2 A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK Completed
  32. Phase 2 A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension Completed
  33. Phase 2 A Study to Assess the Safety and Effects of Intravenous (IV) Conivaptan on the Hepatic Hemodynamic Response in Cirrhotic Patients Completed
  34. Phase 2 A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Liver Cirrhosis Completed
  35. Phase 2 New Treatment Response in People With and Without Cirrhosis From Chronic Hepatitis C Completed
  36. Phase 2 Human Fetal Liver Cell Transplantation in Chronic Liver Failure Completed
  37. Phase 2 Safety and Efficacy of Baclofen for Treatment of Muscle Spasms in Patients With Cirrhosis: A Pilot Study Completed
  38. Phase 2 Continuous Infusion Terlipressin for Patients With Cirrhosis and Refractory Ascites Completed
  39. Phase 2 A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema Completed
  40. Phase 2 Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver Completed
  41. Phase 2 Emricasan, an Oral Caspase Inhibitor, in Subjects With NASH Cirrhosis and Severe Portal Hypertension Completed
  42. Phase 2 MNK6106 for Liver Disease (Hepatic Cirrhosis) That in the Past Has Affected the Brain (Hepatic Encephalopathy) Completed
  43. Phase 2 [18F]FMISO PET/CT After Transcatheter Arterial Embolization in Imaging Tumors in Patients With Liver Cancer Completed
  44. Phase 1 Open Label Single Dose Phase I Trial of BI 201335 to Study Pharmacokinetics and Safety in Patients With Compensated Liver Cirrhosis Completed

Showing the 50 most-cited and recently-updated of 82 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Transcriptomic analysis identifies 846 genes and key pathways associated with MASLD fibrosis progression
Gastroenterology Meta-analysis
Transcriptomic analysis identifies 846 genes and key pathways associated with MASLD fibrosis progression New data reveals how liver scarring progresses in fatty liver disease
This meta-analysis of hepatic transcriptomic data in approximately 1000 patients identifies 846 genes associated with MASLD fibrosis progres…
Researchers identified specific genes and cell changes that drive liver scarring in patients with metabolic dysfunction-associated steatotic…
Sep 16, 2026
Seladelpar 10 mg shows optimal risk-benefit profile for UDCA-refractory primary biliary cholangitis patients
Drug Pipeline Meta-analysis
Seladelpar 10 mg shows optimal risk-benefit profile for UDCA-refractory primary biliary cholangitis patients New data identifies promising treatments for primary biliary cholangitis
This network meta-analysis of 1,540 patients evaluates various therapies for primary biliary cholangitis (PBC) with inadequate response to U…
New research identifies specific medications that may improve liver health and relieve itching for patients with primary biliary cholangitis…
Frontiers Sep 13, 2026
Dioscin shows therapeutic potential for various liver disorders including MASLD and hepatocellular carcinoma
Drug Pipeline Sys. Review
Dioscin shows therapeutic potential for various liver disorders including MASLD and hepatocellular carcinoma Plant Compound Dioscin Shows Promise For Liver Disease
This systematic review evaluates the hepatoprotective effects and pharmacokinetics of Dioscin in various liver diseases. The review conclude…
A plant compound called Dioscin may help protect the liver, but human evidence is still missing and high doses carry risks.
Frontiers Sep 13, 2026
Polyherbal Unani Formulation Targets TGF-beta/Smad, NF-kappaB, and PI3K/Akt Pathways in Fibrosis and Cancer
Drug Pipeline Sys. Review
Polyherbal Unani Formulation Targets TGF-beta/Smad, NF-kappaB, and PI3K/Akt Pathways in Fibrosis and Cancer Polyherbal Unani Formulation shows potential to treat cancer and fibrosis
This systematic review examines the preclinical evidence for a polyherbal Unani formulation containing chebulinic acid, picrosides, flavonoi…
A traditional herbal blend may help fight the scarring and cell changes that make cancer and fibrosis diseases harder to treat.
Frontiers Sep 13, 2026
Prolonged SEMS retention for refractory variceal bleeding allows removal after 387 days
Rheumatology Guideline
Prolonged SEMS retention for refractory variceal bleeding allows removal after 387 days Doctors successfully remove a metal stent after one year of use
This case report describes a 72-year-old woman with decompensated cirrhosis who received a fully covered self-expanding metal stent (SEMS) f…
A new case report shows a metal stent can be safely removed after a year of use, offering a possible path for patients with liver disease.
Frontiers Sep 7, 2026
Phase 2 Trial Evaluating Zalfermin and Semaglutide Combinations for Metabolic Dysfunction Associated Steatohepatitis
Gastroenterology RCT
Phase 2 Trial Evaluating Zalfermin and Semaglutide Combinations for Metabolic Dysfunction Associated Steatohepatitis Trial Shows Semaglutide May Impact Liver Fibrosis in MASLD
A 52-week trial assessed whether zalfermin combined with semaglutide improves liver fibrosis in patients with advanced steatohepatitis.
A new trial suggests semaglutide may improve liver fibrosis in patients with MASLD, while other combinations did not show significant result…
Sep 2, 2026
Multidrug-resistant pathogens are prevalent in cirrhosis with higher rates in lower-middle-income countries
Gastroenterology Meta-analysis
Multidrug-resistant pathogens are prevalent in cirrhosis with higher rates in lower-middle-income countries Gram-negative Bacteria and Resistance Patterns in Cirrhosis Patients
This systematic review and proportional meta-analysis of 2781 clinical infections and 381 colonizations in adults with cirrhosis identifies …
A large review of infections in patients with cirrhosis shows that 60% of bacterial isolates are Gram-negative and many show drug resistance…
Sep 1, 2026
Non-selective beta-blockers reduce mortality risk by 25% in patients with decompensated cirrhosis
Drug Pipeline Meta-analysis
Non-selective beta-blockers reduce mortality risk by 25% in patients with decompensated cirrhosis Beta Blockers May Reduce Mortality Risk in Cirrhosis Patients
This meta-analysis of observational studies involving 120,072 patients found that non-selective beta-blockers (NSBBs) are associated with a …
A large-scale review suggests that non-selective beta-blockers may lower mortality risks for patients with decompensated cirrhosis, especial…
Frontiers Aug 24, 2026
Sarcopenia Assessment Modalities and Mortality Risk Prediction in Patients with Liver Cirrhosis
Nutrition & Obesity Medicine Meta-analysis
Sarcopenia Assessment Modalities and Mortality Risk Prediction in Patients with Liver Cirrhosis Muscle Loss Linked to Higher Mortality Risk in Liver Cirrhosis
Meta-analysis confirms that sarcopenia significantly increases mortality risk in liver cirrhosis patients across multiple imaging and physic…
Patients with liver cirrhosis and muscle loss, known as sarcopenia, face a significantly higher risk of mortality across several different m…
Frontiers Aug 23, 2026
Multidisciplinary teams and bloodless medicine pathways may improve outcomes for acute gastrointestinal bleeding
Rheumatology Meta-analysis
Multidisciplinary teams and bloodless medicine pathways may improve outcomes for acute gastrointestinal bleeding New research looks at better ways to treat internal bleeding
This systematic review synthesizes evidence on organizational models, such as multidisciplinary team programs and transfusion-free pathways,…
Specialized team-based care and bloodless medicine pathways show promise for patients with serious gastrointestinal bleeding.
Frontiers Aug 3, 2026
Multidrug-resistant bacterial infections are prevalent among hospitalized patients with cirrhosis
Gastroenterology Meta-analysis
Multidrug-resistant bacterial infections are prevalent among hospitalized patients with cirrhosis Analysis shows high rates of drug resistant infections in cirrhosis
This meta-analysis examined the prevalence of multidrug-resistant bacterial infections in hospitalized patients with cirrhosis. The findings…
Over one-third of hospitalized patients with liver cirrhosis face infections from bacteria that are hard to treat with standard medications.
Aug 1, 2026
Direct oral anticoagulants reduce thrombotic events and major bleeding in cirrhosis with atrial fibrillation or venous thromboembolism
Cardiology Meta-analysis
Direct oral anticoagulants reduce thrombotic events and major bleeding in cirrhosis with atrial fibrillation or venous thromboembolism Direct oral anticoagulants show promise for patients with liver cirrhosis
A meta-analysis of predominantly observational studies compared direct oral anticoagulants with traditional anticoagulants in patients with …
New analysis suggests direct oral anticoagulants may reduce blood clots and major bleeding risks for patients with liver cirrhosis and heart…
Aug 1, 2026

Questions about Cirrhosis

How common is depression among patients with liver cirrhosis?

Depression is very common in liver cirrhosis, affecting about 37% of patients globally, yet it often goes undiagnosed.

Full answer →
Can the Patient Buddy App help reduce hospital readmissions for my cirrhosis?

Yes, the Patient Buddy App reduced avoidable hospital readmissions in cirrhosis patients by about half in a clinical trial, but discuss with your doctor if it's right for you.

Full answer →